⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of PrimaCure and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
PrimaCure
↗Unknown, Global/Korea-based operations
PrimaCure appears to be a brand/entity primarily focused on aesthetic biotechnology, specifically utilizing exosome technology for skin and scalp rejuvenation. The company emphasizes Korean biotechnology and non-invasive, biologically aligned protocols for aesthetic practices.
Separately, there is a historical entity referred to as Primocure Pharma, Inc., which was a subsidiary of KoDiscovery and involved in the development of anti-cancer therapeutics (KAT-101) for liver and bile duct cancers, having received Orphan Drug Designations in the past. There is also no relation to industrial 'Primocure' ink drying equipment.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Aesthetic products)
Modalities:Exosomes
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Niche Player
LEADERSHIP
Key Executives:
Dr. Mike Lee - CEO and Founder
LINKS
Website:primocure.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with PrimaCure. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.